Meeting
2016 ASCO Annual Meeting
Association of abnormal molecular markers with clonal plasma cell burden in light chain amyloidosis.
Authors
Lindsay Hammons
Medical College of Wisconsin, Milwaukee, WI
Lindsay Hammons , Parameswaran Hari , Ruta Brazauskas , Anita D'Souza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Plasma Cell Disorders
Citation
J Clin Oncol 34, 2016 (suppl; abstr 8063)
DOI
10.1200/JCO.2016.34.15_suppl.8063
Abstract #
8063
Poster Bd #
328
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Evaluating serum-free light chain ratio as a biomarker for multiple myeloma.
First Author: Theresia Akhlaghi
Poster
2022 ASCO Annual Meeting
African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients.
First Author: Theresia Akhlaghi
Poster
2019 ASCO Annual Meeting
Seeking light-chain amyloidosis very early: The SAVE trial—identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma.
First Author: Ping Zhou
Poster
2017 ASCO Annual Meeting
Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).
First Author: Surbhi Sidana